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The molecular pathogenesis of thymomas and thymic carcinomas (TCs) is poorly under-
stood and results of adjuvant therapy are unsatisfactory in case of metastatic disease
and tumor recurrence. For these clinical settings, novel therapeutic strategies are urgently
needed. Recently, limited sequencing efforts revealed that a broad spectrum of genes that
play key roles in various common cancers are rarely affected in thymomas and TCs, sug-
gesting that other oncogenic principles might be important.This made us re-analyze historic
expression data obtained in a spectrum of thymomas and thymic squamous cell carcinomas
(TSCCs) with a custom-made cDNA microarray. By cluster analysis, different anti-apoptotic
signatures were detected in type B3 thymoma and TSCC, including overexpression of
BIRC3 in TSCCs. This was confirmed by qRT-PCR in the original and an independent val-
idation set of tumors. In contrast to several other cancer cell lines, the BIRC3-positive
TSCC cell line, 1889c showed spontaneous apoptosis after BIRC3 knock-down. Targeting
apoptosis genes is worth testing as therapeutic principle in TSCC.
Keywords: thymoma, thymic carcinoma, thymus, apoptosis, gene expression, myasthenia gravis, MTCH2, targeted
therapy
INTRODUCTION
Thymomas comprise a spectrum of unique thymic epithelial
tumors that generally show intratumoral thymopoiesis. They
are subdivided into WHO type A, AB, B1, B2, and B3 thymo-
mas (1, 2), but this classification has been challenged by some
authors (3, 4). Thymic carcinoma also show a spectrum sub-
types that resemble analogously called extrathymic carcinomas
(TCs) (2, 5). However, there is strong evidence (6–13) that thymic
squamous cell carcinomas (TSCCs) and other squamous cell
carcinomas are different entities. Nevertheless, treatments tai-
lored to the unique biology of thymomas and TCs are miss-
ing (14–16) since there are almost no therapeutic targets (9–
13, 17, 18), with few exceptions (e.g., Kit mutations) (12, 13).
Even whole genome sequencing of a stage IVa B3 thymoma
(19) and sequencing of 46 cancer genes in a TSCC (20) dis-
covered no druggable mutations, suggesting that pathways other
than in more common cancers might be operative (19). Con-
sidering this information and reports about the expression of
apoptosis-related proteins in thymic tumors (21) we analyzed
our unpublished gene expression data of thymuses and thymic
tumors that were obtained with a custom-made cDNA microarray
(representing 4606 genes). We found differential expression of
anti-apoptotic genes in B3 thymomas and TSCC and could induce
apoptosis by BIRC3 blockade in the thymic carcinoma cell line,
1889c (22).
PATIENT CHARACTERISTICS AND METHODS
PATIENTS AND TISSUES
Characteristics of the historic tumors (resected before 2004)
stemmed from our data base (23) (Table 1). For the validation set
of recent tumors obtained after 2006 see Table 2. Thymoma classi-
fication and staging followed the WHO and modified Masaoka
system, respectively (2). All carcinomas were TSCCs without
prior chemotherapy. “Combined thymomas” with >10% sepa-
rable components were excluded. Thymocytes from a normal
thymus were purified by Ficoll density gradient centrifugation.
Ethical approval was obtained.
GENE EXPRESSION PROFILING
Gene expression profiling was achieved with a custom cDNA
microarray representing 4606 genes with known relationship to
cancers. To study reproducibility, 11 of 74 biopsies were studied
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Table 1 | Characteristics of patients and tissues:WHO type A, AB, B2, B3 thymomas;TSCC, thymic squamous cell carcinoma; NT, normal thymus;
thymitis, non-neoplastic thymus with lymphofollicular hyperplasia (LFH) from early-onset Myasthenia Gravis (MG) patients; thymocytes,
purified from NT; MG+ (%), %-age of patients with MG.
Diagnosis N Age range (years) Sex (m:f) Masaoka stage (I–IV) MG+ (%) Follow-up
Thymoma
Type A 7 58–77 5:2 I (n=3) 3 (43%) All alive (2/2)
II (n=4)
Type AB 16 33–79 5:11 I (n=6) 10 (62%) All alive (9/9)
II (n=10)












NT 7 1–38 – 0 –
Thymitis 7 32–37 – 7 –
Thymocytes 1 1 – 0 –
DOD, death of disease; n.k., not known.
Table 2 | Characteristics of 36 recent WHO type A and B3 thymomas andTSCCs that served as validation set for cases fromTable 1.
Diagnosis N Age range (years) Sex (m:f) Masaoka stage (I–IV) MG+ (%) Follow-up
Thymoma
Type A 7 71–87 4:3 I (n=2) 1 (14, 3%) unknown
II (n=5)
Type B3 18 35–80 8:12 I (n=2) 6 (33%) Partially known
II (n=6) 2: dead
III (n=4) 1: alive
IV (n=6)
TSCC 11 40–74 9:2 I (n=1) 0 Partially known
II (n=6) 1: dead
III (n=2) 1: alive
IV (2)
in duplicate. Differential gene expression was analyzed by ANOVA
(JMP Genomics, version 4; SAS, Cary, NC, USA).
RT-PCR
Array-based gene expression in the historic tumors was re-
evaluated by qRT-PCR (TaqMan; FAST SYBR Green; Applied
Biosystems) (Table S1 in Supplementary Material). Relative quan-
tification was calculated using the ∆∆Ct method with GAPDH
as standard (Figure S2 in Supplementary Material). For primers
and condition see Table S1 in Supplementary Material. Con-
firmed genes were checked by qRT-PCR in the validation set of
36 tumors.
PATHWAY ANALYSIS
Pathways were studied using Gene Set Enrichment Analysis
(GSEA) (24). Statistical significance (nominal p-value, NP) of
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enrichment scores (ES) was estimated using 1000 rounds of per-
mutations per pathway. To adjust for multiple hypothesis testing,
ES were normalized (“normalized enrichment scores,” NES) tak-
ing pathway size into account. The proportion of false positives
was controlled by calculating the false discovery rate (FDR) for
each NES.
CELL LINES AND TRANSFECTION WITH si-BIRC3
BIRC3+ human cell lines studied here: 1889c (thymic carcinoma)
(22); HaCat (keratinocytes); PC3 (prostate carcinoma); TE167
(rhabdomyosarcoma); A549 (lung carcinoma); MCF7 (breast
carcinoma); HeLa (cervical adenocarcinoma). Culture condi-
tions: RPMI (1889c) or DMEM (all others); 10% fetal bovine
serum, 2 mM l-Glutamine and penicillin/streptomycin; 37°C; 5%
CO2. About 105 cells transfected with 2µM BIRC3 siRNA Flex-
Tube: si00022827 (Qiagen, Hilden, Germany) or scramble siRNA
using High-Perfect transfection reagent (Qiagen; fast forward
transfection protocol) were harvested after 48 h.
WESTERN BLOT, IMMUNOCYTOCHEMISTRY, AND APOPTOSIS
DETECTION
Cell lines and snap frozen tissues were used for Western blot (25).
Methanol-fixed si-BIRC3 transfected cells and scramble siRNA
transfected controls were stained with mouse anti-human cleaved
caspase 3 (1:100), pH 6, Abcam for 1 h (25).
About 105 transfected cells including floating cells were har-
vested, stained at 20°C for 10 min with annexin V-FITC and
Propidium Iodide PI (BD Biosciences), and evaluated for apoptosis
by flow cytometry.
RESULTS
DISTINCT GENE EXPRESSION PROFILES CORRELATE WITH
WHO-DEFINED THYMOMA SUBTYPES
Gene expression profiling of eight cohorts, i.e., type A, AB, B2, B3
thymomas, TSCC, normal thymus, thymuses with thymitis, and
thymocytes revealed 53 differentially expressed gens (p< 10−10).
Based on these genes the cohorts were grouped into two major
clusters: an epithelial-rich cluster with type A and B3 thymomas,
and TSCCs, and a lymphocyte-rich cluster with AB, B2 thymo-
mas, thymuses, and thymocytes (Figure 1). Clustering was closer
between type A and B3 thymomas than between TSCC and B3
thymomas (Figure 1), despite the similar malignant potential of
B3 thymomas and TSCC (22, 26, 27). Thymuses clustered closer
to B2 than to AB thymomas, which may echo the more physiolog-
ical thympoiesis in B2 thymomas (28, 29). GSEA (24)1 of genes
over-expressed throughout the lymphocyte-rich cohorts showed
that 13 out of 19 annotated genes (Frame in Figure 1) play a role
in T cell biology (p< 10−12).
FUNCTIONAL PATHWAYS ENRICHED IN EPITHELIAL-RICH THYMIC
TUMORS
To reduce the impact of confounding thymocytes, we focused
GSEA on type A and B3 thymomas and TSCCs. Using NES of
>1.6 and p< 0.05 between at least two comparisons (24), we
1http://www.broadinstitute.org/gsea/index.jsp
FIGURE 1 | Hierarchical clustering of eight tissue cohorts: type A, AB,
B2, and B3 thymomas; thymic squamous cell carcinomas (TSCCs);
non-neoplastic thymuses (normal and MG-associated thymitis); and
Ficoll gradient-purified thymocytes based on 53 differentially
expressed genes (p< 10−10). The frame delineates 19 genes with
coordinate up-regulation in the lymphocyte-rich cohorts, most of which
(n=13) play a role in lymphocyte biology (for details see text).
retrieved 11 functional pathways (Table 3). All three tumor cohorts
were differentially enriched by all pair-wise comparisons for path-
ways comprising DNA damage response genes. Since enrichment
increased from TSCCs to type A thymomas, this may reflect the
highest genetic instability in TSCCs and lowest in type A thy-
momas (9, 10). Type A thymomas were enriched for three path-
ways: among the “cell migration genes,” over-expressed KAl1 has
anti-metastatic function (30); IL8RB reinforces p53-dependent
senescence (31); and SAA1 expression that has not been noted
in thymomas before, can have pro- or anti-apoptotic functions
in context-dependent manner (32–36). Among the “transcrip-
tional corepressor genes” the tumor suppressor gene ID4 was
over-expressed in type A thymomas; its reduction – as in type B3
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Table 3 | Significantly enriched functional pathways in type A and B3 thymomas andTSCC using normalized enrichment scores (NES) of >1.6
and p<0.05 between at least two comparisons; NP, normalized p-values (24).The “exemplary genes” are the genes with the strongest
(>1.3-fold) significant (p<0.05) differential expression in the indicated Gene Ontology pathway. Genes given in bold are discussed in the text.
Typical for Pathway (gene ontology) Exemplary genes B3_A TSCC_A TSCC_B3
NES NP NES NP NES NP
All DNA damage response signal transduction by P53 class mediator IFI16 1.74 0.01 1.87 0.00 1.71 0.01
A Cell migration IL8RB, KAL1, SAA1 −1.70 0.01 −1.84 0.00 −0.90 0.61
Transcriptional corepressor activity ID4 −1.70 0.01 −1.76 0.00 −1.12 0.31
Cytoplasm organization and biogenesis ITGA6 −1.77 0.00 −1.66 0.00 −0.92 0.57
B3 Structure molecule activity RPS18 −1.98 0.00 0.90 0.67 2.13 0.00
Structural constitute of ribosome RPS6, RPS18 −2.28 0.00 0.78 0.81 2.45 0.00
Translation −1.87 0.00 0.60 0.98 1.79 0.00
ADP binding −1.71 0.01 0.82 0.70 1.90 0.00
RNA binding RPS6 −1.80 0.00 −0.64 0.97 1.74 0.01
C Caspase activation PMAIP1 1.02 0.45 1.67 0.03 1.90 0.00
Antigen binding IGHG3 0.74 0.78 1.66 0.01 1.66 0.02
FIGURE 2 | Cluster analysis of 19 expressed genes in individual
epithelial-predominant type A and B3 thymomas andTSCC based on a
fold-change >1.5, p<10−4 and low variance (var<0.07) in at least one of
the cohorts of tumors. One of the two main clusters (left) harbors all of the
type A thymomas and six of the (“type A-like”) B3 thymomas. The other
cluster harbors all the TSCC and 11 of the (TSCC-like) B3 thymomas. The
frame highlights a cluster of apoptosis-related genes (BIRC3, SCYA20,
PMAIP1, MYC, MTCH2).
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FIGURE 3 | Validation of five differentially expressed genes in
type A and type B3 thymomas and thymic squamous cell
carcinomas (TSCC, C) in the original set of tumors (left column;
seeTable 1) and the validation set (right column; seeTable 2).
BIRC3, PMAIP1/NOXA, and Chitinase3-like1 genes are
over-expressed in TSCC. The pro-apoptotic MTCH2 is expressed in
type A thymomas (and largely missing in TSCC). PIK3R1 is most
significantly expressed in type B3 thymomas.
thymomas and TSCCs – is typical of various cancers (37). These
findings seemingly reflect the lower malignant potential of type A
thymomas (23, 27).
In B3 thymomas, most of the enriched pathways concerned
translation, including down-regulation of the ribosomal protein
genes RPS6 and RPS18, which is rare in other cancers (38). Since
RPS6 is an effector of the AKT/mTOR pathway, we studied expres-
sion of its negative regulators PTEN and PIK3R1 but found them
up-regulated only slightly (p< 10−3) in B3 thymomas. Vice versa,
up-regulation of RPS6 and down-regulation of PTEN and PIK3R1
in TSCCs is typical of aggressive cancers (39, 40).
For the role of caspase activity/apoptosis-related genes in
TSCCs see next paragraph.
APOPTOSIS-RELATED SIGNATURE IN TSCC
Nineteen genes were differentially expressed between type A and
B3 thymomas and TSCC (>1.5-fold and p< 0.0001) and with
low variation (var< 0.07) in at least one tumor subtype (Figure 2,
Table S1 in Supplementary Material). By hierarchical clustering,
type A thymomas and TSCCs formed distinct groups, while 6
out of 17 B3 thymomas were clustered with the type A thymo-
mas and 11 with the TSCCs (Figure 2). The B3 thymoma subsets
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FIGURE 4 | Correlation between BIRC3 mRNA and protein levels in type A (five cases) and type B3 (six cases) thymomas andTSCC (seven cases).
Levels of mRNA and protein were higher in TSCCs than in thymomas. mRNA was quantified using real time PCR with GPDH as reference, β-actin was used as
loading control in western blots.
were not different with respect to age, sex, and tumor stage (not
shown) but 9 of 10 myasthenia-associated B3 thymomas belonged
to the “TSCC-like” subset. Figure 2 also depicts apoptosis-related
genes that are co-up-regulated in TSCCs, two with anti-apoptotic
(BIRC3; SCYA20) and two with pro-apoptotic function (PMAIP1;
MYC). Importantly, the pro-apoptotic MTCH2 gene (41, 42)
was down-regulated in TSCCs as also confirmed by qRT-PCR
(Figure 3, left column; Table S1 in Supplementary Material)
and validated in more recently obtained tumors (Figure 3, right
column).
KNOCK-DOWN OF BIRC3 INDUCES APOPTOSIS IN THYMIC
CARCINOMA CELL LINE 1889c
Among differentially expressed genes, we selected BIRC3 for func-
tional analysis, because (i) it is a member of the inhibitors of
apoptosis (IAPs) gene family (43) that serves key oncogenic roles
in many cancers (44, 45); (ii) BIRC3 protein was over-expressed
in parallel with mRNA in most TSCC biopsies compared to thy-
momas (Figure 4); and, (iii) the thymic carcinoma cell line, 1889c
(22) with strong BIRC3 expression was available (Figure S2 in
Supplementary Material). siRNA-mediated BIRC3 knock-down
(Figures 5A,B) induced spontaneous apoptosis in 50% of 1889c
cells within 48 h as shown by cytology, expression of activated
caspase 3 and annexin 5 (Figures 5C–E). 1889c cells and HaCat
keratinocytes were more sensitive toward BIRC3 knock-down than
all other cancer cell lines tested (Figures 5A–E; Figure S3 in Sup-
plementary Material), despite similar BIRC3 mRNA levels (Figure
S2 in Supplementary Material).
DISCUSSION
The major finding here is the so far unreported (13, 19, 46) obser-
vation of different expression profiles of apoptosis-related genes
in TSCCs and B3 thymomas in two independent sets of thymic
epithelial tumors. Significantly, anti-apoptotic BIRC3 – a mem-
ber of the “IAPs” gene family that mainly blocks the extrinsic
apoptosis pathway – was over-expressed at the mRNA and protein
level in most TSCCs compared to type A and B3 thymomas; and
BIRC3-positive 1889c thymic carcinoma cells showed stronger
spontaneous apoptosis on BIRC3 knock-down in vitro than all
other cell lines tested. In addition, other than the thymomas, the
TSCCs showed lower mRNA expression of the MTCH2 gene that
induces apoptosis by cooperation with tBID to facilitate BAX-
mediated mitochondrial cytochrome c release (47). These findings
suggest that TSCCs suffer from attenuation of both the extrinsic
and intrinsic apoptosis pathway. This is complemented in TSCCs
by down-regulation of PIK3R1 (Figure 3) that normally inter-
feres with various pro-survival cascades, including Akt signaling
(40, 41). By contrast, the anti-apoptotic make-up of B3 thymomas
in the current study was due to the down-regulation of the pro-
apoptotic PMAIP1/NOXA gene (Figure 3) that plays a role in the
mitochondrial apoptosis pathway and drug resistance (48).
A caveat here is the limited coverage of the transcriptome
by our applied microarray. While key apoptosis-related gens like
BCL2, MCL1, BIRC2, BIRC5, BCL2L1 were represented but did
not show differential expression between TSCC and B3 thymomas
(not shown), other important genes (e.g., BIRC4/XIAP, BIRC6-8,
BAX, BBC3/PUMA, and BIM ) were missing and warrant fur-
ther analysis. Despite these limitations, our findings could have
a translational perspective, since advanced tumor stage, limited
resectability, and common relapses (13–15, 23, 26, 49–51) are fre-
quent indications in TSCCs for (neo-)adjuvant therapies that may
be critically attenuated by apoptosis resistance of the target tumor
cells (52). Indeed, therapeutic options are already available (e.g.,
#NCT00977067; #NCT01078649)2 or up-coming (53), includ-
ing drugs against BIRC3 (54) and strategies to induce PMAIP1
(48). RT-PCR-based expression profiles of anti-apoptotic genes
are worth testing as “biomarkers” in clinical trials aiming to break
treatment resistance in thymic cancers.
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FIGURE 5 | Several cell lines (1889c, HaCat,TE167, and PC3) were
transfected using si-BIRC3 for 48h, which significantly repressed
expression of (A) Birc3 mRNA ****p<0.0001 in 1889c, HaCat and
TE167 cells and ***p=0.0002 in PC3) and (B) Birc3 protein. After
transfection. Changes of the cytology of transfected cells is shown in
(C). Cells were stained with an antibody to cleaved caspase 3 for
apoptosis detection (immunoperoxidase ×20) (D). FACS analysis to
quantify apoptosis using Annexin V-FITCS/PI (E). All experiments were
done in triplicate and each measurement in duplicate. Similar low levels of
apoptosis following si-BIRC3 transfection were observed in A549 (lung
carcinoma); MCF7 (breast carcinoma); and HeLa (cervical
adenocarcinoma) cells.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at http://www.frontiersin.org/Journal/10.3389/fonc.2013.
00316/abstract
Table S1 | Characteristics of the 19 genes with significantly different
expression in epithelial-rich thymic epithelial tumors (Figure 2): type A and
B3 thymomas andTSCCs. Functions are: AD, adhesion; AP, apoptosis; Diff,
differentiation; IR, immune response; M, migration; P, proliferation; TD, T cell
development; IF, inflammation; TR, tissue remodeling. The differential
expression of all genes in the original set of tumors was confirmed by qRT-PCR
(see also Figure 3).
Table S2 | Primer sequences and annealing temperatures used to confirm
and validate by qRT-PCR the expression of those genes that were found to
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be differentially expressed on microarray analysis and are depicted in
Figure 3 and Figure S1 in Supplementary Material.
Figure S1 | Confirmation and validation of cKIT gene expression using
qRT-PCR inTSCC.
Figure S2 | Semi-quantitative determination of BIRC3 mRNA levels in
several cell lines using standard PCR with 10 ng cDNA as template for each
sample. BIRC3 expression was detectable in all cell lines except the
rhabdomyosarcoma cell lines RH30 and CRL2061. GAPDH was used as control.
Figure S3 | Evaluation of annexin V-FITC/PI labeled cells using FACS 48 h
after BIRC3 knock-down. The transfected 1889c thymic carcinoma cells
showed the highest level of apoptosis (50%) compared to HaCat (40%), TE167
(10%, **p=0.0097), A459 (20%, *p= 0.0432), PC3 (<10%, **p=0.0082),
MCF7 (<20%, *p=0.0154), and HeLa (<10%, **p=0.0079). The results
represent the mean of three independent experiments, each with duplicate
measurements.
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